STUTTGART, Germany I December 19, 2016 I Since La Merie Publishing released its last Competitor Analysis report about antibody-drug conjugates in April 2013, the number of ADCs in active clinical development has doubled from 33 in 2013 to 65 at the end of the year 2016. Among them are eight ADCs in late stage development or under regulatory review. More than 20 ADCs are in the IND stage or undergoing IND-enabling studies. The current analysis identified further 58 preclinical stage ADC projects and 22 ADC discovery programs. However, the number of ADCs discontinued from clinical development also has increased indicating a healthy R&D field.
The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates and describes the competitive landscape of antibody-drug conjugates (ADCs) in a tabular format by target, payload, R&D phase and company as of December 2016.
Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Among the most popular targets of ADC developments identified in the search are Her2, CD30, CD33, CD22, CD19, PSMA, 5T4, EGF-R, and CEACAM5, in addition to unique targets identified by companies with proprietary target discovery programs.
With the increasing number of ADCs in development and of companies with in-house ADC technology development, new payloads are being evaluated in early clinical studies, but the one magic ADC technology has not yet been defined. Rather, quite a number of ADCs generated with next generation technologies regarding payload, drug:antibody ratio, linker, or antibody format are in clinical proof-of-concept studies.
The report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ can be acquired online at PipelineReview.com or by contacting sales@lamerie.com
About La Merie
La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.
SOURCE: La Merie Publishing
Post Views: 347
STUTTGART, Germany I December 19, 2016 I Since La Merie Publishing released its last Competitor Analysis report about antibody-drug conjugates in April 2013, the number of ADCs in active clinical development has doubled from 33 in 2013 to 65 at the end of the year 2016. Among them are eight ADCs in late stage development or under regulatory review. More than 20 ADCs are in the IND stage or undergoing IND-enabling studies. The current analysis identified further 58 preclinical stage ADC projects and 22 ADC discovery programs. However, the number of ADCs discontinued from clinical development also has increased indicating a healthy R&D field.
The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates and describes the competitive landscape of antibody-drug conjugates (ADCs) in a tabular format by target, payload, R&D phase and company as of December 2016.
Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Among the most popular targets of ADC developments identified in the search are Her2, CD30, CD33, CD22, CD19, PSMA, 5T4, EGF-R, and CEACAM5, in addition to unique targets identified by companies with proprietary target discovery programs.
With the increasing number of ADCs in development and of companies with in-house ADC technology development, new payloads are being evaluated in early clinical studies, but the one magic ADC technology has not yet been defined. Rather, quite a number of ADCs generated with next generation technologies regarding payload, drug:antibody ratio, linker, or antibody format are in clinical proof-of-concept studies.
The report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ can be acquired online at PipelineReview.com or by contacting sales@lamerie.com
About La Merie
La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com and www.PipelineReview.com, the Biologics News Center and Online Store of La Merie Publishing.
SOURCE: La Merie Publishing
Post Views: 347
